Connect with us

Replica Analytics’ new estimator uses synthetic data for more reliable evaluation of re-identification risk in datasets

Published

on

OTTAWA, ON, July 19, 2022 /PRNewswire/ – Replica Analytics, an Aetion company, has unveiled a novel approach to use synthetic data for a more accurate assessment of re-identification risks in datasets, to better manage privacy risks and enable greater data sharing in healthcare and other sectors.

“Re-identification risk is the probability that an adversary will correctly match a record in a dataset with a real person and until now, there has been no sufficiently reliable measure of this risk,” said Dr. Khaled El Emam, Senior Vice-President and General Manager of Replica Analytics, the premier science-based synthetic data generation technology provider to the healthcare industry. “Access to data and sharing de-identified datasets remain a challenge, in part due to privacy concerns. The re-identification risk estimator we have developed should help data custodians overcome those challenges.”

Most existing estimators provide a proxy for risk based on strong assumptions, as they cannot calculate the risk on a population because real population data is rarely available. Replica’s estimator leverages data synthesis technology to simulate the unavailable population dataset, so that re-identification risks can be calculated much more accurately. Synthetic data generation (SDG) involves training a machine learning model to master the statistical patterns and properties of a real dataset. The trained model, when implemented properly, is then used to create a synthetic dataset which maintains the traits of the original dataset, but with no one-to-one mapping back to a person, so the synthetic data mitigates privacy risks.

Measuring re-identification risk using a synthetic estimator to enable data sharing, a study recently published by the journal, PLOS ONE, includes a detailed analysis of the concepts behind Replica’s new risk estimator, an evaluation of its performance and relevant case studies. The results show that the estimator reliably outperforms other approaches, across different dataset sizes and varying complexity, achieving a high degree of accuracy, and offering a consistent estimate of the probability of re-identification risk. The study was also the focus of a webinar and blog post.

The new approach is another example of the usefulness and effectiveness of SDG technology in assessing and mitigating privacy risks and enabling data sharing. Replica’s estimator can now be used through the Replica Synthesis software to better assess re-identification risks in real datasets. If the risk is deemed too high, organizations can choose to synthesize the data and then use the company’s privacy assurance functionality to measure any risk in the synthetic data to demonstrate that it is much lower than the real data.

About Replica Analytics, an Aetion company

Replica Analytics is the premier science-based SDG technology provider to the healthcare industry. The company is a pioneer in the development of unique technologies for generating privacy-protective synthetic data that maintain the statistical properties of real-world data (RWD). The company was acquired in late 2021 by Aetion, the leading regulatory-grade real-world evidence (RWE) technology provider. Replica Synthesis software provides a full suite of synthetic data generation and evaluation capabilities that can solve multiple grand challenges facing the life sciences industry, and health research in general. For more information, visit: https://replica-analytics.com/.

About Aetion

Aetion is a healthcare analytics company that delivers real-world evidence for the manufacturers, purchasers, and regulators of medical treatments and technologies. The Aetion Evidence Platform® analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on safety, effectiveness, and value. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs healthcare’s most critical decisions—what works best, for whom, and when—to guide product development, commercialization, and payment innovation. Learn more at aetion.com and follow us at @aetioninc.

View original content:https://www.prnewswire.com/news-releases/replica-analytics-new-estimator-uses-synthetic-data-for-more-reliable-evaluation-of-re-identification-risk-in-datasets-301589358.html

SOURCE Replica Analytics

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

IGCS International Announces Strategic Equity Investment by Lacks Enterprises

Published

on

By

DALLAS, April 22, 2026 /PRNewswire/ — IGCS International, a CVE-certified SDVOSB and leading provider of mission support and MRO supplies to the U.S. Department of Defense and federal agencies, today announced that Lacks Enterprises has acquired an equity stake in the company.

The strategic investment combines IGCS’s expertise in government supply chain, logistics, and MRO solutions with Lacks Enterprises’ advanced manufacturing capabilities, including electroplating, injection molding, composites, and testing for aerospace and defense.

“IGCS has built a strong track record supporting the Department of Defense… Partnering with Lacks Enterprises allows us to integrate cutting-edge manufacturing innovation into our offerings,” said Russ Spears, President of IGCS International.

Media Contact: Russ Spears, 214-733-7278, russ@igcsintl.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/igcs-international-announces-strategic-equity-investment-by-lacks-enterprises-302750824.html

SOURCE IGCS International

Continue Reading

Technology

Shoulder Innovations to Report First Quarter 2026 Financial Results on May 13, 2026

Published

on

By

GRAND RAPIDS, Mich., April 22, 2026 /PRNewswire/ — Shoulder Innovations, Inc. (“Shoulder Innovations”) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced it will release financial results for the first quarter of 2026 after market close on Wednesday, May 13, 2026.

Management will host a conference call to discuss financial results beginning at 4:30 p.m. ET / 1:30 p.m. PT on May 13, 2026. Those interested in listening to the conference call may do so by dialing (877) 407-8216 for domestic callers or (412) 902-1015 for international callers and providing access code 13759613. A live and archived webcast of the event will be available in the “Investor Relations” section of the Shoulder Innovations website at https://ir.shoulderinnovations.com/.

About Shoulder Innovations
Shoulder Innovations is a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, with a current offering of advanced implant systems for shoulder arthroplasty. These systems are a core element of Shoulder Innovations’ ecosystem, which is designed to improve core components of shoulder surgical care – preoperative planning, implant design and procedural efficiency – to benefit each stakeholder in the care chain. Shoulder Innovations’ ecosystem is also comprised of enabling technologies, efficient instrument systems, specialized support and surgeon-to-surgeon collaboration. Together, these elements seek to address the long-standing clinical and operational challenges in the shoulder surgical care market by delivering predictable outcomes, procedural simplicity, and efficiency across all sites of care.

Contact
Brian Johnston or Sam Bentzinger 
Gilmartin Group LLC 
ir@shoulderinnovations.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/shoulder-innovations-to-report-first-quarter-2026-financial-results-on-may-13-2026-302750154.html

SOURCE Shoulder Innovations

Continue Reading

Technology

Accuray to Report Third Quarter Fiscal 2026 Financial Results on May 6, 2026

Published

on

By

MADISON, Wis., April 22, 2026 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) will report financial results for the third quarter of fiscal year 2026, ended March 31, 2026, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on May 6, 2026.

The conference call dial-in numbers are 1-833-316-0563 (USA) or 1-412-317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call’s conclusion for one week. The replay number is 1-855-669-9658 (USA) or 1-412-317-0088 (international), conference ID: 4178502.

A live webcast of the call will also be available from the Investor Relations section of the company’s website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available until Accuray announces its results for the fourth quarter of fiscal 2026.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Investor and Media Contact
Steve Monroe
VP, Financial Planning & Analysis, Accuray
Investor.relations@accuray.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-to-report-third-quarter-fiscal-2026-financial-results-on-may-6-2026-302750641.html

SOURCE Accuray Incorporated

Continue Reading

Trending